The results of a preclinical study by lymphoma researchers at Weill Cornell Medicine suggest that an emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some ...
The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma ...
HUTCHMED has received conditional approval from the National Medical Products Administration (NMPA) in China for TAZVERIK® (tazemetostat), marking it as the first EZH2 inhibitor approved in the ...
A randomized phase II trial presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium found that adding the EZH2 inhibitor mevrometostat to enzalutamide (Xtandi) ...
A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published in Science Advances ...
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results